Content-Transfer-Encoding: |
7bit |
Sender: |
|
Subject: |
|
From: |
|
Date: |
Tue, 19 Aug 2003 19:00:33 EDT |
Content-Type: |
text/plain; charset="US-ASCII" |
MIME-Version: |
1.0 |
Reply-To: |
|
Parts/Attachments: |
|
|
In a message dated 8/19/03 1:05:26 PM Eastern Daylight Time,
[log in to unmask] writes:
> At the same time, a drug company is about to begin advanced testing of a
> shot created to curb jaundice in high-risk newborns by halting their
> bodies' production of bilirubin for about a week. The drug's inventor,
> Rockefeller University's Dr. Attallah Kappas, predicts it could
> dramatically cut the number of babies - roughly 100,000 - who undergo
> expensive, cumbersome light therapy for jaundice.
>
Dear Friends:
Another chilling example of technology run rampant. How will high risk
be defined? What will the impact be of re-routing a natural body defense
mechanism? What about keeping mothers and babies together for unrestricted
breastfeeding? That is the only evidence-based practice to reduce or prevent jaundice
that I know of.
warmly,
Nikki Lee
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|